All News

2018

October

Media Release / Oct 19, 2018

Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden

Read More
Media Release / Oct 18, 2018

Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms

Read More
Media Release / Oct 18, 2018

Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth

Read More
Novartis Financial Results – Q3 2018
Featured News / Oct 18, 2018

Novartis Financial Results – Q3 2018

Today, Novartis CEO Vas Narasimhan announced the company’s financial results for the third quarter of 2018.

Read More
Media Release / Oct 16, 2018

Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis

Read More
Media Release / Oct 11, 2018

Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access

Read More
Media Release / Oct 10, 2018

Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis

Read More
Marjorie Eiref (left) and Beata Henry getting the job done
Story / Oct 10, 2018

Women in Science: Marjorie Eiref

Marjorie Eiref, Head of Operations for Neuroscience Research at Novartis, describes how her family medical history has impacted her career.

Read More
Media Release / Oct 10, 2018

Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden

Read More
Media Release / Oct 09, 2018

Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More